Isis-AstraZeneca Collaboration For Antisense Drugs Gets HSR Clearance

(RTTNews) - Isis Pharmaceuticals, Inc. (ISIS) Friday said its collaboration with AstraZeneca (AZN, AZN.L) to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

AstraZeneca will pay Isis a $65 million up-front payment. Isis is also eligible to receive development and regulatory milestones for each program that AstraZeneca advances to clinical development.

Isis is also eligible to earn tiered double-digit royalties on annual net sales for each program.